Pharmacological inhibition of receptor-interacting protein kinase 2 (RIPK2) elicits neuroprotective effects following experimental ischemic stroke.

MLA

Larochelle, Jonathan, et al. “Pharmacological Inhibition of Receptor-Interacting Protein Kinase 2 (RIPK2) Elicits Neuroprotective Effects Following Experimental Ischemic Stroke.” Experimental Neurology, vol. 377, July 2024, p. 114812. EBSCOhost, https://doi.org/10.1016/j.expneurol.2024.114812.

APA

Larochelle, J., Howell, J. A., Yang, C., Liu, L., Gunraj, R. E., Stansbury, S. M., de Oliveira, A. C. P., Baksh, S., & Candelario-Jalil, E. (2024). Pharmacological inhibition of receptor-interacting protein kinase 2 (RIPK2) elicits neuroprotective effects following experimental ischemic stroke. Experimental Neurology, 377, 114812. https://doi.org/10.1016/j.expneurol.2024.114812

Chicago

Larochelle, Jonathan, John Aaron Howell, Changjun Yang, Lei Liu, Rachel E Gunraj, Sofia M Stansbury, Antonio Carlos Pinheiro de Oliveira, Shairaz Baksh, and Eduardo Candelario-Jalil. 2024. “Pharmacological Inhibition of Receptor-Interacting Protein Kinase 2 (RIPK2) Elicits Neuroprotective Effects Following Experimental Ischemic Stroke.” Experimental Neurology 377 (July): 114812. doi:10.1016/j.expneurol.2024.114812.